CGON
CG Oncology, Inc. Common stock
$64.25
-0.34
(-0.53%)
Mkt Cap
5.67B
Volume
628,373
52W Range
23.65-75.5
Sector
Healthcare
Beta
0.42
EPS (TTM)
-2.34
P/E Ratio
-19.94
Revenue (TTM)
5.07M
Rev Growth (5Y)
-21.0%
EPS Growth (5Y)
N/A
Company Description
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.04M | 1.14M | 204,000 | 191,000 | 10.36M |
| Net Income | (161.00M) | (88.04M) | (48.61M) | (35.44M) | (12.84M) |
| EPS | -2.08 | -1.41 | -1.02 | -0.66 | -0.28 |
| Free Cash Flow | (132.48M) | (78.95M) | (45.68M) | (29.82M) | (13.75M) |
| FCF / Share | -1.71 | -1.26 | -0.69 | -0.45 | -0.21 |
| Operating CF | (132.35M) | (78.71M) | (45.68M) | (29.80M) | (13.65M) |
| Total Assets | 791.59M | 754.80M | 199.30M | 147.75M | 58.69M |
| Total Debt | 7.02M | 238,000 | 1.03M | 15.94M | 15.13M |
| Cash & Equiv | 32.49M | 257.07M | 8.27M | 88.14M | 53.61M |
| Book Value | 752.60M | 733.38M | 184.79M | 125.18M | 40.25M |
| Return on Equity | -0.21 | -0.12 | -0.26 | -0.28 | -0.32 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.08M | 2.32M | 1.67M | 0 | 52,000 | 456,000 | 43,000 | 111,000 | 529,000 | 1,000 | 9,000 | 0 |
| Net Income | (60.20M) | (41.31M) | (43.81M) | (41.43M) | (34.45M) | (31.80M) | (20.41M) | (18.90M) | (16.93M) | (16.12M) | (11.77M) | (11.61M) |
| EPS | -0.71 | -0.52 | -0.57 | -0.54 | -0.45 | -0.49 | -0.30 | -0.28 | -0.25 | -0.33 | -0.28 | -0.17 |
| Free Cash Flow | (57.25M) | (36.22M) | (38.99M) | (27.97M) | (29.29M) | (20.87M) | (15.92M) | (16.13M) | (26.02M) | (16.06M) | (10.84M) | (10.79M) |
| FCF / Share | -0.68 | -0.47 | -0.51 | -0.37 | -0.38 | -0.32 | -0.24 | -0.24 | -0.39 | -0.24 | -0.16 | -0.16 |
| Operating CF | (56.94M) | (36.22M) | (38.89M) | (27.96M) | (29.28M) | (20.66M) | (15.92M) | (16.12M) | (26.01M) | (16.06M) | (10.85M) | (10.79M) |
| Total Assets | 1.14B | 791.59M | 729.91M | 701.45M | 728.18M | 754.80M | 552.47M | 564.33M | 579.11M | 199.30M | 211.88M | N/A |
| Total Debt | 7.58M | 7.02M | 7.24M | 994,000 | 1.04M | 238,000 | 296,000 | 355,000 | 404,000 | 1.03M | 517,000 | N/A |
| Cash & Equiv | 33.70M | 32.49M | 45.15M | 14.62M | 41.47M | 257.07M | 43.41M | 25.16M | 77.47M | 8.27M | 10.27M | N/A |
| Book Value | 1.09B | 752.60M | 687.64M | 670.36M | 704.76M | 733.38M | 536.77M | 552.36M | 568.94M | 184.79M | 199.87M | N/A |
| Return on Equity | -0.06 | -0.05 | -0.06 | -0.06 | -0.05 | -0.04 | -0.04 | -0.03 | -0.03 | -0.09 | -0.06 | N/A |
CGON News
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears
CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet